Essential medicines in Hungary

ESSENTIAL
MEDICINES
IN HUNGARY
Arete-Zoe, LLC
Date: July 22, 2017
Data lock point: May 28, 2017
https://www.aretezoe.com/

"We have essentially been avoiding this elephant in the
room for the past twenty years, never daring to state
what we know: namely that the use of public healthcare
services does not reflect the needs of society, but
rather the interests of the institutional system."
Dr. Zoltán Ónodi-Szűcs,
Hungarian Secretary of State for Health (Haynes, 2017)

System organ class WHO EML
WHO EML
Available
WHO EML
Unavailable
WHO EML
Unavailable
%
NL EML
Both EM Lists
(overlap)
A – Alimentary tract and metabolic diseases 34 26 8 24% 38 13
B – Blood and blood-forming organs 30 27 3 10% 5 2
C – Cardiovascular system 25 20 5 20% 81 13
D – Dermatologicals 21 11 10 48% 14 3
G - Genito-urinary system, sex hormones 19 11 8 42% 32 4
H – Hormones, excl. sex hormones and
insulins
11 11 0 0% 6 3
J – Systemic anti-infectives 119 83 36 30% 29 19
L – Anti-neoplastic agents, immunomodulants 45 39 6 13% 17 7
M – Musculoskeletal system 6 4 2 33% 18 1
N – Nervous system 37 35 2 5% 62 11
P – Anti-parasitics, insecticides, repellents 36 7 29 81% 0 0
R – Respiratory system 10 7 3 30% 24 4
S – Sensory organs 13 7 6 46% 18 2
V - Various 21 12 9 43% 2 1
TOTAL 427 301 121 30% 346 83
FIG. 1 - Summary (table): Availability of essential medicines by organ class

FIG. 2 – Summary (graph): Essential medicines lists by organ class
34
30
25
21 19
11
119
45
6
37 36
10
13
21
38
5
81
14
32
6
29
17 18
62
0
24
18
2
13
2
13
3 4 3
19
7
1
11
0
4 2 1
0
20
40
60
80
100
120
140
WHO List of Essential Medicines
National List of Essential Medicines
Drug listed on both Lists

FIG. 3 – Summary (graph): Availability of essential medicines lists by organ class
0
20
40
60
80
100
120
140
WHO List of EM Unavailable
WHO List of EM Available

ALIMENTARY TRACT AND
METABOLISM (A)

FIG. 4 – Summary (graph): Availability of registered products (A) – WHO EM List
70
50
42
35
32
29
19
16
13 12
10
5 5 4 4 4 4 3 3 2 2 1 1 1 1 1 0 0 0 0 0 0 0 0
0
10
20
30
40
50
60
70
80
insulin,fast-acting
metformin
omeprazole
gliclazide
insulin,intermediate
ondansetron
ascorbicacid
ranitidine
cholecalciferol
multienzymes
loperamide
sennaglycosides
thiamine
hyoscinebutylbromide
glibenclamide
lactulose
retinol
medicinalcharcoal
pyridoxine
metoclopramide
Othermineralproducts
atropin
Oralrehydrationsalts
sulfasalazine
calciumgluconate
zincsulfate
hyoscinehydrobr
docusatesodium
paromomycin
hydrocortisone
ergocalciferol
nicotinamide
riboflavin
sodiumfluoride
Approvals (number of registrations)

FIG. 5 – Summary (graph): Availability of registered products (A) – National EML
76
72
51 50 50
42
35 35
31 29
23
20 19 17 16 16 15 14 12 12 11 10 10 10 9 8 7 7 6 5 4 4 4 4 3 3 3 2
0
10
20
30
40
50
60
70
80
pantoprazole
glimepiride
esomeprazole
metformin
rabeprazole
omeprazole
gliclazide
pioglitazone
repaglinide
ondansetron
lansoprazole
Calcium,combinations
ascorbicacid
sitagliptin
ranitidine
multivitaminsandminerals
Al3+,Mg2+,Ca2+combinations
granisetron
benzydamine
multienzymes
drotaverine
ordinarysalts
famotidine
loperamide
orlistat
acarbose
silymarin
calciumcarbonate
alfacalcidol
thiamine
sucralfate
lactulose
sibutramine
retinol
domperidone
medicinalcharcoal
pyridoxine
miglustat

FIG. 6 – Summary (graph): Availability of registered products (A) – WHO
EML and National EML combined
76
72
70
51 50 50
42
35 35
32 31
29
23
20 19
17 16 16 15 14 13 12 12 11 10 10 10 9 8 7 7 6 5 5 4 4 4 4 4 4 3 3 3 2 2 2 1 1 1 1 1 0 0 0 0 0 0 0 0
0
10
20
30
40
50
60
70
80
pantoprazole
glimepiride
insulin,fast-acting
esomeprazole
metformin
rabeprazole
omeprazole
gliclazide
pioglitazone
insulin,intermediate
repaglinide
ondansetron
lansoprazole
Calcium,combinations
ascorbicacid
sitagliptin
ranitidine
Al3+,Mg2+,Ca2+Combinations
granisetron
cholecalciferol
benzydamine
multienzymes
drotaverine
loperamide
saltcombinations
famotidine
orlistat
acarbose
silymarin
calciumcarbonate
alfacalcidol
sennaglycosides
thiamine
hyoscinebutylbromide
glibenclamide
lactulose
retinol
sucralfate
sibutramine
medicinalcharcoal
pyridoxine
domperidone
metoclopramide
Othermineralproducts
miglustat
atropin
sulfasalazine
calciumgluconate
zincsulfate
hyoscinehydrobr
docusatesodium
paromomycin
hydrocortisone
ergocalciferol
nicotinamide
riboflavin
sodiumfluoride

FIG 7 – Stomatologicals (A01) and Acid related disorders (A02)
12
15
10
16
10
42
76
23
50 51
4
0
10
20
30
40
50
60
70
80
benzydamine
Al3+,Mg2+,Ca2+combinations
ordinarysalts
ranitidine
famotidine
omeprazole
pantoprazole
lansoprazole
rabeprazole
esomeprazole
sucralfate
NL NL NL WHO, NL NL WHO, NL NL NL NL NL NL
A01AD02 A02AD A02AD01 A02BA02 A02BA03 A02BC01 A02BC02 A02BC03 A02BC04 A02BC05 A02BX02

FIG. 8 – Drugs for functional GIT disorders (A03),
antiemetics and antinauseants (A04)
11
1
4
2
3
29
14
0
0
5
10
15
20
25
30
35
drotaverine atropin hyoscine
butylbromide
metoclopramide domperidone ondansetron granisetron hyoscine hydrobr
NL WHO WHO WHO NL WHO, NL NL WHO
A03AD02 A03BA01 A03BB01 A03FA01 A03FA03 A04AA01 A04AA02 A04AD01

FIG. 9 – Bile and liver therapy (A05),
drugs for constipation (A06), anti-diarrheals (A07)
7
0
5
4
0
3
1
10
0
1
0
2
4
6
8
10
12
silymarin
docusatesodium
sennaglycosides
lactulose
paromomycin
medicinalcharcoal
loperamide
hydrocortisone
sulfasalazine
NL WHO WHO WHO, NL WHO WHO, NL WHO WHO, NL WHO WHO
A05BA03 A06AA02 A06AB06 A06AD11 A07AA6 A07BA01 A07CA A07DA03 A07EA02 A07EC01

FIG. 10 – Anti-obesity drugs (A08) and digestives incl. enzymes (A09)
4
9
12
0
2
4
6
8
10
12
14
sibutramine orlistat multienzymes
NL NL WHO, NL
A08AA10 A08AB01 A09AA02

FIG. 11 – Drugs used in diabetes (A10)
70
32
50
4
35
72
8
35
17
31
0
10
20
30
40
50
60
70
80
insulin, fast-
acting
insulin,
intermediate
metformin glibenclamide gliclazide glimepiride acarbose pioglitazone sitagliptin repaglinide
WHO WHO WHO, NL WHO WHO, NL NL NL NL NL NL
A10AB A10AC A10BA02 A10BB01 A10BB09 A10BB12 A10BF01 A10BG03 A10BH01 A10BX02

FIG. 12 - Vitamins (A11)
16
4
0
6
13
5
19
0
3
0
0
2
4
6
8
10
12
14
16
18
20
retinol
ergocalciferol
alfacalcidol
cholecalciferol
thiamine
ascorbicacid
nicotinamide
pyridoxine
riboflavin
NL WHO, NL WHO NL WHO WHO, NL WHO, NL WHO WHO, NL WHO
A11AA03 A11CA01 A11CC01 A11CC03 A11CC05 A11DA01 A11GA01 A11HA01 A11HA02 A11HA04

FIG. 13 - Mineral supplements (A12),
other alimentary tract & metabolism drugs (A16)
1
7
20
1
0
2 2
0
5
10
15
20
25
calcium gluconate calcium carbonate Calcium,
combinations
zinc sulfate sodium fluoride Other mineral
products
miglustat
WHO NL NL WHO WHO WHO NL
A12AA03 A12AA04 A12AX A12CB01 A12CD01 A12CX A16AX06

Unavailable WHO EML
ATC Code Active ingredient
A04AD01 hyoscine hydrobromide
A06AA02 docusate sodium
A07AA6 paromomycin
A07EA02 hydrocortisone
A11CC01 ergocalciferol
A11HA01 nicotinamide
A11HA04 riboflavin
A12CD01 sodium fluoride

BLOOD AND BLOOD-
FORMING ORGANS (B)

FIG. 14 – Summary (graph): Availability of registered products (B) –
WHO EM List and National EM List combined
68
60
29
17
10 10
8 8 8 7
5 5 5 5 5 4 4 4 3 3 3 3 3 2 2 2 2 2 1 1 0 0 0
0
10
20
30
40
50
60
70
80

FIG 15 - Anti-thrombotic agents (B01)
8
2
10
8
10
60
5
29
2
7
1
0
10
20
30
40
50
60
70
warfarin
heparin
dalteparin
enoxaparin
nadroparin
clopidogrel
ticlopidine
acetylsalicylicacid
triflusal
cilostazol
streptokinase
WHO, NL WHO WHO WHO WHO WHO, NL NL WHO NL NL WHO
B01AA03 B01AB01 B01AB04 B01AB05 B01AB06 B01AC04 B01AC05 B01AC06 B01AC18 B01AC23 B01AD01

FIG 16 – Anti-hemorrhagics (B02)
3 2
5
68
0
10
20
30
40
50
60
70
80
trenexamic acid phytomenadione coagulation factors IX, II, VII
and X
coagulation factor VIII
WHO WHO WHO WHO
B02AA02 B02BA01 B02BD01 B02BD02

FIG 17 – Anti-anemic preparations (B03)
4 4
5
1
3
0
1
2
3
4
5
6
Iron bivalent, oral Iron trivalent, oral Iron in combination
with folic acid
hydroxycobalamin folic acid
WHO WHO WHO WHO WHO
B03AA B03AB B03AD B03BA03 B03BB01

FIG 18 – Blood substitutes and perfusion solutions (B05)
2
4
0 0
8
17
5
3
2
5
3 3
0
0
2
4
6
8
10
12
14
16
18
plateletconcentratesandwholeblood
dextran
redbloodcells
freshfrozenplasma
carbohydratesforparenteralnutrition
electrolytes
electrolyteswithcarbohydrates
mannitol
isotonicsolutions
potassiumchloride
sodiumbicarbonate
sodiumchloride
magnesiumsulfate
WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO
B05A B05AA05 B05AX01 B05AX03 B05BA03 B05BB01 B05BB02 B05BC01 B05DA B05XA01 B05XA02 B05XA03 B05XA05

Unavailable WHO EML
B05AX01 red blood cells
B05AX03 fresh frozen plasma
B05XA05 magnesium sulfate

CARDIOVASCULAR
SYSTEM (C)

FIG. 20A – Summary (graph): Availability of registered products (C) – National EML
146
105
93 93
75 74
67 66
58 58 57
53 51
45 44 44 44
40
0
20
40
60
80
100
120
140
160

FIG. 20B – Summary (graph): Availability of registered products (C) – National EML
39
37 37
35
31
25
23 23 22 21 20 19 18 18 17 17 16 15 15
13 13
0
5
10
15
20
25
30
35
40
45

FIG 19 – Summary (graph): Availability of registered products (C) – WHO EML
58
53
44
39
37
31
18
12
10 9 8 8
6
3 3 2 2 2 2 1 0 0 0 0 0
0
10
20
30
40
50
60
70

FIG. 20C – Summary (graph): Availability of registered products (C) – National EML
12 12 12 12 12 12 12
11
10 10 10 10 10 10
9 9 9
0
2
4
6
8
10
12
14

FIG. 20D – Summary (graph): Availability of registered products (C) – National EML
8 8 8 8 8 8 8
7 7 7 7
6 6 6 6 6
4
3 3 3 3 3
2 2 2
0
1
2
3
4
5
6
7
8
9

FIG. 21A – Summary (graph): Availability of registered products (C) –
WHO EML and National EML combined
146
105
93 93
75 74
67 66
58 58 57
53 51
45 44 44 44
40 39 37 37 35
31
25 23 23 22 21 20 19 18 18 17 17 16
0
20
40
60
80
100
120
140
160

FIG. 21B – Summary (graph): Availability of registered products (C) –
15 15
13 13
12 12 12 12 12 12 12
11
10 10 10 10 10 10
9 9 9
8 8 8 8 8 8 8
7 7 7 7
0
2
4
6
8
10
12
14
16

FIG. 21C – Summary (graph): Availability of registered products (C) –
6 6 6 6 6 6
4
3 3 3 3 3 3
2 2 2 2 2 2 2
1
0 0 0 0 0
0
1
2
3
4
5
6
7

FIG. 22 - Cardiac therapy (C01)
2 2
10
2
1
6
0
18
0
7
15
20
0
5
10
15
20
25
digoxin
lidocaine
propafenone
amiodaron
dopamine
epinephrine(adrenaline)
ephedrine
glyceryltrinitrate
isosorbidedinitrate
isosorbidemononitrate
trimetazidine
ivabradine
WHO WHO NL WHO WHO WHO WHO WHO, NL WHO NL NL NL
C01AA05 C01BB01 C01BC03 C01BD01 C01CA04 C01CA24 C01CA26 C01DA02 C01DA08 C01DA14 C01EB15 C01EB17

FIG. 23 - Antihypertensives (C02)
3
21
3
23
12
0 0
17
0
5
10
15
20
25
methyldopa
(levorotatory)
moxonidine rilmenidine doxazosin urapidil hydrazaline nitroprusside bosentan
WHO NL NL NL NL WHO WHO NL
C02AB01 C02AC05 C02AC06 C02CA04 C02CA06 C02DB02 C02DD01 C02KX01
Approvals (number of registrations) WHO List of Essential Medicines

FIG. 24 – Diuretics (C03) and peripheral vasodilatators (C04)
2
15
8
10
22
0
2
8
0
5
10
15
20
25
hydrochlorothiazide
indapamide
furosemide
spironolactone
eplerenone
amiloride
hydrochlorothiazideandpotassium-
sparingagents
pentoxifylline
WHO NL WHO, NL WHO, NL NL WHO NL NL
C03AA03 C03BA11 C03CA01 C03DA01 C03DA04 C03DB01 C03EA01 C04AD03

FIG. 25 – Vasoprotectives (C05) and beta-blocking agents (C07)
4
7
3 3
39
8
44
19
37
7
16
13
0
5
10
15
20
25
30
35
40
45
50
procaine calcium
dobesilate
propranolol sotalol metoprolol atenolol bisoprolol nebivolol carvedilol bisoprolol
and
thiazides
bisoprolol
and
amlodipine
metoprolol
and
ivabradine
NL NL WHO, NL NL WHO, NL WHO, NL WHO, NL NL WHO, NL NL NL NL
C05AD05 C05BX01 C07AA05 C07AA07 C07AB02 C07AB03 C07AB07 C07AB12 C07AG02 C07BB07 C07FB07 C07FX05

FIG. 26 - Calcium-channel blockers (C08)
53
12
9
3
6
12
6 6
0
10
20
30
40
50
60
amlodipine felodipine nifedipine nitrendipine lercanidipine verapamil diltiazem amlodipine and
diuretics
WHO, NL NL WHO, NL NL NL WHO, NL NL NL
C08CA01 C08CA02 C08CA05 C08CA08 C08CA13 C08DA01 C08DB01 C08GA02

FIG. 27 - Renin-angiotensin system: ACE inhibitors (C09A)
7
31
18
67 66
12
9 9
0
10
20
30
40
50
60
70
80
captopril enalapril lisinopril perindopril ramipril quinapril fosinopril trandolapril
NL WHO, NL NL NL NL NL NL NL
C09AA01 C09AA02 C09AA03 C09AA04 C09AA05 C09AA06 C09AA09 C09AA10

FIG. 28 - Renin-angiotensin system: ACE inhibitors in combinations (C09B)
10
58
23
13
8
10
44
25
8
0
10
20
30
40
50
60
70
enalapril and
diuretics
perindopril and
diuretics
ramipril and
diuretics
quinapril and
diuretics
enalapril and
lercanidipine
lisinopril and
amlodipine
perindopril and
amlodipine
perindopril,
amlodipine
and
indapamide
perindopril and
bisoprolol
NL NL NL NL NL NL NL NL NL
C09BA02 C09BA04 C09BA05 C09BA06 C09BB02 C09BB03 C09BB04 C09BX01 C09BX02

FIG. 29 - Renin-angiotensin system: Angiotensin II antagonists (C09C)
57
105
93
37
51
12
0
20
40
60
80
100
120
losartan valsartan irbesartan candesartan telmisartan olmesartan
medoxomil
NL NL NL NL NL NL
C09CA01 C09CA03 C09CA04 C09CA06 C09CA07 C09CA08

FIG. 30 - Renin-angiotensin system: Angiotensin II antagonists
in combinations (C09D)
44
74 75
17
40
12
45
8 10
0
10
20
30
40
50
60
70
80
losartananddiuretics
valsartananddiuretics
irbesartananddiuretics
candesartananddiuretics
telmisartananddiuretics
olmesartanmedoxomilanddiuretics
valsartanandamlodipine
losartanandamlodipine
olmesartanmedoxomil,amlodipineand
hydrochlorothiazide
NL NL NL NL NL NL NL NL NL
C09DA01 C09DA03 C09DA04 C09DA06 C09DA07 C09DA08 C09DB01 C09DB06 C09DX03

FIG. 31 - Lipid modifying agents (C10)
58
6 11
146
93
3 6 2 2
10 8
35
12
0
20
40
60
80
100
120
140
160
simvastatin
pravastatin
fluvastatin
atorvastatin
rosuvastatin
gemfibrozil
fenofibrate
ciprofibrate
omega-3-triglyceridesincl.otherestersandacids
ezetimibe
simvastatinandezetimibe
atorvastatinandamlodipine
rosuvastatinandamlodipine
WHO, NL NL NL NL NL NL NL NL NL NL NL NL NL
C10AA01 C10AA03 C10AA04 C10AA05 C10AA07 C10AB04 C10AB05 C10AB08 C10AX06 C10AX09 C10BA02 C10BX03 C10BX09

Unavailable WHO EML
C01CA26 ephedrine
C01DA08 isosorbide dinitrate
C02DB02 hydrazaline
C02DD01 nitroprusside
C03DB01 amiloride

DERMATOLOGICALS (D)

FIG. 32 – Summary (graph): Availability of registered products (D) – WHO EML
14
6
5
3 3 3
2 2
1 1 1
0 0 0 0 0 0 0 0 0 0
0
2
4
6
8
10
12
14
16

FIG. 33 – Summary (graph): Availability of registered products (D) – National EML
14
10 10
8
6 6 6
5 5
4 4
3 3 3
0
2
4
6
8
10
12
14
16

FIG. 34 – Summary (graph): Availability of registered products (D) –
14
10 10
8
6 6 6 6
5 5
4 4
3 3 3 3 3
2 2
1 1 1
0 0 0 0 0 0 0 0 0 0
0
2
4
6
8
10
12
14
16

FIG. 35 - Antifungals for dermatological use (D01)
0
5
0
3
0 0
6
4
0
14
0
2
4
6
8
10
12
14
16
nystatin clotrimazole miconazole ketoconazole salicylic acid selenium
sulfide
ciclopirox amorolfine griseofulvin terbinafine
WHO NL WHO NL WHO WHO NL NL WHO WHO, NL
D01AA01 D01AC01 D01AC02 D01AC08 D01AE12 D01AE13 D01AE14 D01AE16 D01BA01 D01BA02

FIG. 36 - Emollients and protectives (D02), antipsoriatics (D05) and antibiotics
and chemotherapeutics for dermatological use (D06)
2
1
6
2
1
3
0
1
2
3
4
5
6
7
Zinc products carbamide antipsoriatics for
topical use
mupirocin silver sulfadiazine podophyllotoxin
WHO WHO WHO WHO WHO WHO
D02AB D02AE01 D05A D06AX09 D06BA01 D06BB04

FIG. 37 – Corticosteroids for dermatological use (D07)
3
8
1
10
6
3
0
2
4
6
8
10
12
hydrocortisone hydrocortisone butyrate betamethasone mometasone clobetasol betamethasone
WHO NL WHO NL NL NL
D07AA02 D07AB02 D07AC01 D07AC13 D07AD01 D07XC01

FIG. 38 – Antiseptics and disinfectants (D08)
0 0
3
4
0 0 0
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
chlorhexidine chloroxylenol povidone-iodine octenidine,
combinations
isopropanol potassium
permanganate
ethanol
WHO WHO WHO, NL NL WHO WHO WHO
D08AC02 D08AE05 D08AG02 D08AJ57 D08AX05 D08AX06 D08AX08

FIG. 39 – Anti-acne preparations (D10)
5
6
10
0
2
4
6
8
10
12
benzoyl peroxide erythromycin isotretinoin
WHO, NL NL NL
D10AE01 D10AF02 D10BA01

Unavailable WHO EML
D01AA01 nystatin
D01AC02 miconazole
D01AE12 salicylic acid
D01AE13 selenium sulfide
D01BA01 griseofulvin
D08AC02 chlorhexidine
D08AE05 chloroxylenol
D08AX05 isopropanol
D08AX06 potassium permanganate
D08AX08 ethanol

GENITO-URINARY SYSTEM
AND SEX HORMONES (G)

FIG. 40 – Summary (graph): Availability of registered products (G) – WHO EML
10
9 9
8
7
5
3
2
1 1 1
0 0 0 0 0 0 0 0
0
2
4
6
8
10
12

FIG. 41 – Summary (graph): Availability of registered products (G) – National EML
97
83
32 31
28
18 16
11 11 10 10
7 6 6 6 6 5 5 5 5 5 5 4 3 3 3 2 2 2 2 2
0
20
40
60
80
100
120

FIG. 42 – Summary (graph): Availability of registered products (G) – WHO
97
83
323128
1816
11111010 9 9 8 7 6 6 6 6 5 5 5 5 5 5 4 3 3 3 3 2 2 2 2 2 1 1 1 0 0 0 0 0 0 0 0
0
20
40
60
80
100
120
sildenafil
drospirenoneandethinylestradiol
gestodeneandethinylestradiol
tamsulosin
tadalafil
desogestrelandethinylestradiol
finasteride
estradiol
vardenafil
clotrimazole
terazosin
Intravaginalcontraceptives
progesteron
testosteron
levonorgestrelandethinylestradiol
desogestrel
norethisteroneandestrogen
raloxifene
tolterodine
levonorgestrel
dienogestandethinylestradiol
cyproterone
oxybutynin
solifenacin
cyproteroneandestrogen
medroxyprogesterone
tibolone
dutasteride
econazole
vaginalringwithprogestogenandestrogen
levonorgestrelandestrogen
chlormadinoneandethinylestradiol
misoprostol
clomifene
mifepristone
ergometrine
plasticIUDwithcopper
plasticIUDwithprogesteron
norethisteroneandethinylestradiol
medroxyprogesteroneandestrogen
norethisterone
levonorgestrel
etonorgestrel

FIG. 43 - Antiinfectives and antiseptics (G01), other gynecologicals (G02)
10
2
0
1
0 0
9
2
0
2
4
6
8
10
12
clotrimazole
econazole
ergometrine
misoprostol
plasticIUDwithcopper
plasticIUDwithprogesteron
Intravaginalcontraceptives
vaginalringwithprogestogenandestrogen
WHO, NL NL WHO WHO WHO WHO WHO NL
G01AF02 G01AF05 G02AB03 G02AD06 G02BA02 G02BA03 G02BB G02BB01

FIG. 44 – Hormonal contraceptives for systemic use: Progestogens and
estrogens, fixed combinations (G03AA)
0
7
0
18
32
83
2
5
0
10
20
30
40
50
60
70
80
90
norethisteroneandethinylestradiol
levonorgestrelandethinylestradiol
medroxyprogesteroneandestrogen
drospirenoneandethinylestradiol
chlormadinoneandethinylestradiol
dienogestandethinylestradiol
WHO WHO, NL WHO NL NL NL NL NL
G03AA05 G03AA07 G03AA08 G03AA09 G03AA10 G03AA12 G03AA15 G03AA16

FIG. 45 – Hormonal contraceptives for systemic use: Progestogens and
estrogens, sequential preparations (G03AB)
2
5
2
0
1
2
3
4
5
6
levonorgestrel and
estrogen
desogestrel and
ethinylestradiol
gestodene and
ethinylestradiol
WHO, NL NL NL
G03AB03 G03AB05 G03AB06

FIG. 46 –Progestogens (G03AC) and emergency contraceptives (G03AD)
0 0
3
0
6
5
0
1
2
3
4
5
6
7
norethisterone
levonorgestrel
medroxyprogesterone
etonorgestrel
desogestrel
levonorgestrel
WHO only WHO only WHO only WHO only NL only Both
G03AC01 G03AC03 G03AC06 G03AC08 G03AC09 G03AD01

FIG. 47 – Androgens (G03B), estrogens (G03C), progestogens (G03D)
androgens and female hormones comb. (G03E),
and progestogens and estrogens comb. (G03F)
8
11
3
9
6
3
0
2
4
6
8
10
12
testosteron
estradiol
tibolone
progesteron
WHO NL NL WHO NL NL
G03BA03 G03CA03 G03CX01 G03DA04 G03FA01 G03FB05

FIG. 48 – Gonadotropins and other ovulation stimulants (G03G), antiandrogens
(G03H) and other sex hormones and modulators of the genital system (G03X)
1
5
4
1
6
0
1
2
3
4
5
6
7
clomifene cyproterone cyproterone and
estrogen
mifepristone raloxifene
WHO NL NL WHO NL
G03GB02 G03HA01 G03HB01 G03XB01 G03XC01

FIG. 49 – Urologicals (G04)
5 6 5
97
28
11
31
10
16
3
0
20
40
60
80
100
120
oxybutynin tolterodine solifenacin sildenafil tadalafil vardenafil tamsulosin terazosin finasteride dutasteride
NL NL NL NL NL NL NL NL NL NL
G04BD04 G04BD07 G04BD08 G04BE03 G04BE08 G04BE09 G04CA02 G04CA03 G04CB01 G04CB02

Unavailable WHO EML
G02AB03 ergometrine
G02BA02 plastic IUD with copper
G02BA03 plastic IUD with progesteron
G03AA05 norethisterone and ethinylestradiol
G03AA08 medroxyprogesterone and estrogen
G03AC01 norethisterone
G03AC03 levonorgestrel
G03AC08 etonorgestrel

HORMONES FOR SYSTEMIC
USE, EXCL. SEX HORMONES
AND INSULINS (H)

FIG. 50 – Summary (graph): Availability of registered products (H) –
25
19
18
15
13
10
9
6
3 3
2
1 1 1
0
5
10
15
20
25
30

FIG. 51 – Pituitary and hypothalamic hormones and analogues (H01),
corticosteroids for systemic use (H02)
19
3
1
6
18
2
9
0
2
4
6
8
10
12
14
16
18
20
desmopressin oxytocin fludrocortisone dexamethasone methylprednisolon prednisolone hydrocortisone
WHO, NL WHO WHO WHO WHO, NL WHO WHO
H01BA02 H01BB02 H02AA02 H02AB02 H02AB04 H02AB06 H02AB09

FIG. 52 – Thyroid therapy (H03), pancreatic hormones (H04),
calcium homeostasis (H05)
25
1
3
1
10
15
13
0
5
10
15
20
25
30
levothyroxine
sodium
propylthiouracil Iodine therapy Glucagon calcitonin (salmon
synthetic)
cinacalcet paricalcitol
WHO, NL WHO WHO WHO NL NL NL
H03AA01 H03BA02 H03CA H04AA01 H05BA01 H05BX01 H05BX02

ANTIINFECTIVES FOR
SYSTEMIC USE (J)

FIG. 53 – Summary (graph): Availability of registered products (J) – WHO EML
(values <4 included in table 56C)
49
47 47
41
39
36
30
20
17
15 15 14 14 13 12 12 11 11
9 9 9 8 8 8 8 7 7 7 7 6 6 5 5 5 5 5 4 4 4 4 4
0
10
20
30
40
50
60
levofloxacin
amoxicillin&enzymeinhibitor
Bacterialandviralvaccines,combined
fluconazol
ciprofloxacin
azithromycin
clarithromycin
amoxicillin
immunoglobulins,normalhuman,IV
vancomycin
efavirenz(EFVorEFZ)
ceftriaxone
aciclovir
ribavirin
ceftazidime
lamivudine(3TC)
doxycycline
hepatitisBvaccine
ofloxacin
stavudine(d4T)
tenofovirdisoproxil
clindamycin
nevirapine(NVP)
oseltamivir
hepatitisAvaccine
cefixime
imipenemandenzymeinhibitor
linezolid
darunavir
cefotaxime
atazanavir
phenoxymethylpenicillin
valganciclovir
abacavir+lamivudine
emtricitabine+tenofovir
immunoglobulins,normalhuman,for…
amphotericinB
ritonavir(r)
encephalitis,tick-borne,inactivated,wholevirus
Rabiesvaccine
papillomavirus(humantypes6,11,16,18)

FIG. 54 – Summary (graph): Availability of registered products (J) – National EML
49
47
41
39
36
30
27
23
20
15
13 13 12 11
9 9 8 8 8 7 7 6 5 5
3 3 3 2 2
0
10
20
30
40
50
60
levofloxacin
amoxicillinandenzymeinhibitor
fluconazol
ciprofloxacin
azithromycin
clarithromycin
voriconazole
cefuroxime
amoxicillin
efavirenz(EFVorEFZ)
ribavirin
moxifloxacin
lamivudine(3TC)
doxycycline
ofloxacin
tenofovirdisoproxil
clindamycin
nevirapine(NVP)
itraconazole
linezolid
norfloxacin
valaciclovir
valganciclovir
famciclovir
lymecycline
sulfamethoxazole+trimethoprim
lamivudine+zidovudine(ZDVor…
fosfomycin
ketoconazole

FIG. 55A – Summary (graph): Availability of registered products (J) –
49
47 47
41
39
36
30
27
23
20
17
15 15 14 14 13 13 12 12 11 11
9 9 9
0
10
20
30
40
50
60

FIG. 55B – Summary (graph): Availability of registered products (J) –
8 8 8 8 8
7 7 7 7 7
6 6 6
5 5 5 5 5 5
4 4 4 4 4
0
1
2
3
4
5
6
7
8
9

FIG. 55C – Summary (table): Availability of registered products (J) –
WHO EML and National EML combined (1-3 registrations)
lymecycline Typhoid vaccines
ampicillin papillomavirus (human types 16, 18)
sulfamethoxazole + trimethoprim benzylpenicillin
gentamicin procain benzylpenicilin
amikacin cefazolin
metronidazole erythromycin
saquinavir (SQV) nitrofurantoin
lamivudine + zidovudine (ZDV or AZT) isoniazid
meningococcal vaccines ethambutol
pneumococcus, purified polysaccharides Ag bedaquiline
Poliomyelitis vaccine delamanid
Rota virus diarrhea vaccines simeprevir
Varicella zoster vaccines efavirenz + emtricitabine + tenofovir
fosfomycin sofosbuvir
ketoconazole dasabuvir
p-aminosalicylic acid ledipasvir + sofosbuvir
rifampicin Cholera vaccines
pyrazinamid anti-D immunoglobulin
rifampicin and isoniazid tetanus immunoglobulin
abacavir (ABC) tetanus toxoid
daclatasvir hemophilus influenzae B, purified antigen conjugated
tuberculosis, live attenuated
encephalitis, Japanese, inactivated, whole virus
Yellow fever vaccines

FIG. 55D – Summary (table): Availability of registered products (J) – WHO EML
and National EML combined (Not available)
chloramphenicol clofazimine
benzathin benzylpenicilin dapsone
cloxacillin lopinavir + ritonavir (LPV/r)
cefalexin zidovudine (ZDV or AZT)
trimethoprim entecavir
sulfadiazine lamivudine + nevirapine + zidovudin
streptomycin lamivudine + nevirapine + stavudine
kanamycin ombitasvir + paritaprevir + ritonavir
spectinomycin diphtheria antitoxin
flucytosine snake venom antiserum
cycloserine rabies immunoglobulin
rifabutin diphtheria toxoid
rifapentine pertussis vaccine
capreomycin measles vaccine, live attenuated
protionamide mumps vaccine, live attenuated
ethionamide Rubella vaccines
terizidone
ethambutol and isoniazid
rifampicin, pyrazinamide and isoniazid
rifampicin, pyrazinamide, ethambutol and isoniazid

FIG. 56 - Antibacterials (J01): Tetracyclines (J01A) amphenicols (J01B)
11
3
0
0
2
4
6
8
10
12
doxycycline lymecycline chloramphenicol
WHO, NL NL WHO
J01AA02 J01AA04 J01BA01

FIG. 57 - Antibacterials (J01): Beta-lactams – penicillins (J01C)
3
20
1
5
0 1 0
47
0
5
10
15
20
25
30
35
40
45
50
ampicillin
amoxicillin
benzylpenicillin
phenoxymethylpenicillin
benzathinbenzylpenicilin
procainbenzylpenicilin
cloxacillin
amoxicillinandenzymeinhibitor
WHO WHO, NL WHO WHO WHO WHO WHO WHO, NL
J01CA01 J01CA04 J01CE01 J01CE02 J01CE08 J01CE09 J01CF02 J01CR02

FIG. 58 - Antibacterials (J01): Beta-lactams – non-penicilline (J01D)
0
1
23
6
12
14
7 7
0
5
10
15
20
25
cefalexin cefazolin cefuroxime cefotaxime ceftazidime ceftriaxone cefixime imipenem and
enzyme inhibitor
WHO WHO NL WHO WHO WHO WHO WHO
J01DB01 J01DB04 J01DC02 J01DD01 J01DD02 J01DD04 J01DD08 J01DH51

FIG. 59 - Antibacterials (J01): Sulphonamides and trimethoprim (J01E) and
macrolides, linkosamides and streptogramins (J01F)
0 0
3
1
30
36
8
0
5
10
15
20
25
30
35
40
trimethoprim sulfadiazine sulfamethoxazole +
trimethoprim
erythromycin clarithromycin azithromycin clindamycin
WHO WHO WHO, NL WHO WHO, NL WHO, NL WHO, NL
J01EA01 J01EC02 J01EE01 J01FA01 J01FA09 J01FA10 J01FF01

FIG. 60 - Antibacterials (J01): Aminoglycosides (J01G)
0
3
0
3
0
0.5
1
1.5
2
2.5
3
3.5
streptomycin gentamicin kanamycin amikacin
WHO WHO WHO WHO
J01GA01 J01GB03 J01GB04 J01GB06

FIG. 61 - Antibacterials (J01): Quinolones (J01M)
9
39
7
49
13
0
10
20
30
40
50
60
ofloxacin ciprofloxacin norfloxacin levofloxacin moxifloxacin
WHO, NL WHO, NL NL WHO, NL NL
J01MA01 J01MA02 J01MA06 J01MA12 J01MA14

FIG. 62 - Antibacterials (J01): Other antibacterials (J01X)
15
3
1
2
0
7
0
2
4
6
8
10
12
14
16
vancomycin
metronidazole
nitrofurantoin
fosfomycin
spectinomycin
linezolid
WHO WHO WHO NL WHO WHO, NL
J01XA01 J01XD01 J01XE01 J01XX01 J01XX04 J01XX08

FIG. 63 – Antimycotics for systemic use (J02)
4
2
41
8
27
0
0
5
10
15
20
25
30
35
40
45
amphotericin
B
ketoconazole fluconazol itraconazole voriconazole flucytosine
WHO NL WHO, NL NL NL WHO
J02AA01 J02AB02 J02AC01 J02AC02 J02AC03 J02AX01

FIG. 64A – Antimycobacterials (J04): Tuberculosis (J04A)
2
0
2
0 0 0
1
0 0
0
0.5
1
1.5
2
2.5
p-aminosalicylic
acid
cycloserine rifampicin rifabutin rifapentine capreomycin isoniazid protionamide ethionamide
WHO WHO WHO WHO WHO WHO WHO WHO WHO
J04AA01 J04AB01 J04AB02 J04AB04 J04AB05 J04AB30 J04AC01 J04AD01 J04AD03

FIG. 64B – Antimycobacterials (J04) Tuberculosis (J04A) and leprosy (J04B)
2
1
0
1 1
2
0 0 0 0 0
0
0.5
1
1.5
2
2.5
pyrazinamid
ethambutol
terizidone
bedaquiline
delamanid
rifampicinandisoniazid
ethambutolandisoniazid
rifampicin,pyrazinamideandisoniazid
rifampicin,pyrazinamide,ethambutoland
isoniazid
clofazimine
dapsone
WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO
J04AK01 J04AK02 J04AK03 J04AK05 J04AK06 J04AM02 J04AM03 J04AM05 J04AM06 J04BA01 J04BA02

FIG. 65 – Antivirals for systemic use (J05): Nucleosides and nucleotides excl.
reverse transcriptase inhibitors (J05AB) and Protease inhibitors (J05AE)
14
13
5
6
5
3
4
6
7
1
0
0
2
4
6
8
10
12
14
16
aciclovir
ribavirin
famciclovir
valaciclovir
valganciclovir
saquinavir(SQV)
ritonavir(r)
atazanavir
darunavir
simeprevir
lopinavir+ritonavir(LPV/r)
WHO WHO, NL NL NL WHO, NL WHO WHO WHO WHO WHO WHO
J05AB01 J05AB04 J05AB09 J05AB11 J05AB14 J05AE01 J05AE03 J05AE08 J05AE10 J05AE14 J05AE30

FIG. 66 – Antivirals for systemic use (J05): Nucleoside and nucleotide reverse
transcriptase inhibitors (J05AF), Non-nucleoside reverse transcriptase
inhibitors (J05G) and Neuraminidase inhibitors (J05AH)
0
9
12
2
9
0
8
15
8
0
2
4
6
8
10
12
14
16
zidovudine
(ZDV or AZT)
stavudine
(d4T)
lamivudine
(3TC)
abacavir (ABC) tenofovir
disoproxil
entecavir nevirapine
(NVP)
efavirenz (EFV
or EFZ)
oseltamivir
WHO WHO WHO, NL WHO WHO, NL WHO WHO, NL WHO, NL WHO
J05AF01 J05AF04 J05AF05 J05AF06 J05AF07 J05AF10 J05AG01 J05AG03 J05AH02

FIG. 67 – Antivirals for systemic use (J05): Antivirals for treatment of HIV
infections, combinations (J05AR) and Other antivirals (J05AX)
3
5 5
0
1
0
2
1 1 1
0
0
1
2
3
4
5
6
lamivudine+zidovudine(ZDVorAZT)
abacavir+lamivudine
emtricitabine+tenofovir
lamivudine+nevirapine+zidovudin
efavirenz+emtricitabine+tenofovir
lamivudine+nevirapine+stavudine
daclatasvir
sofosbuvir
dasabuvir
ledipasvir+sofosbuvir
ombitasvir+paritaprevir+ritonavir
WHO, NL WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO
J05AR01 J05AR02 J05AR03 J05AR05 J05AR06 J05AR07 J05AX14 J05AX15 J05AX16 J05AX65 J05AX66

FIG. 68 – Immune sera and immunoglobulins (J06)
0 0
5
17
2 2
0
0
2
4
6
8
10
12
14
16
18
diphtheria antitoxin snake venom
antiserum
immunoglobulins,
normal human, for
extravascular
administration
immunoglobulins,
normal human, for
intravascular
administration
anti-D
immunoglobulin
tetanus
immunoglobulin
rabies
immunoglobulin
WHO WHO WHO WHO WHO WHO WHO
J06AA01 J06AA03 J06BA01 J06BA02 J06BB01 J06BB02 J06BB05

FIG. 69A – Vaccines (J07): Bacterial vaccines (J07A)
1 1
3
2 2 2
4
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
cholera,
inactivated, whole
cell
hemophilus
influenzae B,
combinations with
tetanus toxoid
Meningococcal
vaccines
meningococcus
A,C,Y,W-135,
tetravalent purified
polysaccharides
antigen
meningococcus C,
purified
polysaccharides
antigen conjugated
meningococcus
A,C,Y,W-135,
tetravalent purified
polysaccharides
antigen conjugated
pertussis, purified
antigen,
combinations with
toxoids
J07AE01 J07AG51 J07AH J07AH04 J07AH07 J07AH08 J07AJ52

FIG. 69B – Vaccines (J07): Bacterial vaccines (J07A)
3 3 3
2
20
1
2
4 4
0
5
10
15
20
25
pneumococcus,purifiedpolysaccharides
antigen
pneumococcus,purifiedpolysaccharides
antigenconjugated
pneumococcuspurifiedpolysaccharides
antigenandhaemophilusinfluenzae,
conjugated
tetanustoxoid
tetanustoxoid,combinationswith
diphtheriatoxoid
tuberculosis,liveattenuated
Typhoidvaccines
Otherbacterialvaccines
encephalitis,tickborne,inactivated,whole
virus
J07AL01 J07AL02 J07AL52 J07AM01 J07AM51 J07AN01 J07AP03 J07AX J07BA01

FIG. 70A – Vaccines (J07): Viral vaccines (J07B)
4
1
7
21
2
11
8
6
0
5
10
15
20
25
encephalitis, tick
borne,
inactivated,
whole virus
encephalitis,
Japanese,
inactivated,
whole virus
influenza,
inactivated,
whole virus
influenza,
inactivated, split
virus or surface
antigen
influenza, live
attenuated
hepatitis B,
purified antigen
hepatitis A,
inactivated,
whole virus
hepatitis A and B
vaccines,
combinations
J07BA01 J07BA02 J07BB01 J07BB02 J07BB03 J07BC01 J07BC02 J07BC20

FIG. 70B– Vaccines (J07): Viral vaccines (J07B)
4
3
1
2
4
2
1
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
measles,
combinations with
mumps and
rubella, live
attenuated
measles,
combinations with
mumps, rubella
and varicella, live
attenuated
Poliomyelitis
vaccines
poliomyelitis,
trivalent,
inactivated, whole
virus
rabies, inactivated,
whole virus
rota virus, live
attenuated
rota virus,
pentavalent, live,
reassorted
J07BD52 J07BD54 J07BF J07BF03 J07BG01 J07BH01 J07BH02

FIG. 70C– Vaccines (J07): Viral vaccines (J07B)
3
1 1 1
4
2
1
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
varicella, live
attenuated
zoster, live
attenuated
yellow fever, live
attenuated
Papillomavirus
vaccines
papillomavirus
(human types 6,
11, 16, 18)
papillomavirus
(human types 16,
18)
smallpox, live
attenuated
J07BK01 J07BK02 J07BL01 J07BM J07BM01 J07BM02 J07BX

FIG. 71 – Vaccines (J07): Bacterial and viral vaccines combined (J07C)
1 1
4
7
3
8
1 1
0
1
2
3
4
5
6
7
8
9
Bacterialandviralvaccines,combined
diphtheria-poliomyelitis-tetanus
diphtheria-pertussis-poliomyelitis-
tetanus
Diphtheria-hepatitisB-pertussis-tetanus
diphtheria-hemophilusinfluenzaeB-
pertussis-poliomyelitis-tetanus
diphtheria-hemophilusinfluenzaeB-
pertussis-poliomyelitis-tetanus-hepatitis
B
vakcina(kombinált)
diphtheria-pertussis-poliomyelitis-
tetanus-hepatitisB
J07CA J07CA01 J07CA02 J07CA05 J07CA06 J07CA09 J07CA11 J07CA12

Unavailable WHO EML
Antibacterials
J01BA01 chloramphenicol
J01CE08 benzathin benzylpenicilin
J01CF02 cloxacillin
J01DB01 cefalexin
J01EA01 trimethoprim
J01EC02 sulfadiazine
J01GA01 streptomycin
J01GB04 kanamycin
J01XX04 spectinomycin
Antimycotics
J02AX01 flucytosine

Unavailable WHO EML
Antimycobacterials
J04AB01 cycloserine
J04AB04 rifabutin
J04AB05 rifapentine
J04AB30 capreomycin
J04AD01 protionamide
J04AD03 ethionamide
J04AK03 terizidone
J04AM03 ethambutol and isoniazid
J04AM05 rifampicin, pyrazinamide and isoniazid
J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid
J04BA01 clofazimine
J04BA02 dapsone

Unavailable WHO EML
Antivirals
J05AE30 lopinavir + ritonavir (LPV/r)
J05AF01 zidovudine (ZDV or AZT)
J05AF10 entecavir
J05AR05 lamivudine + nevirapine + zidovudin
J05AR07 lamivudine + nevirapine + stavudine
J05AX66 ombitasvir + paritaprevir + ritonavir
Immune sera and immuoglobulins
J06AA01 diphtheria antitoxin
J06AA03 snake venom antiserum
J06BB05 rabies immunoglobulin

Unavailable WHO EML
Vaccines
J07AF01 diphtheria toxoid
J07AJ01 pertussis vaccine
J07BD01 measles vaccine, live attenuated
J07BE01 mumps vaccine, live attenuated
J07BJ Rubella vaccines

ANTINEOPLASTIC AND
IMMUNOMODULATING
AGENTS (L)

FIG. 72A – Summary (graph): Availability of registered products (L) – WHO EML
60
40 40
34 33 33
31
22
20 19 19
13
11 10 10 10 10 9 8 8 7 7 6
0
10
20
30
40
50
60
70

FIG. 72B – Summary (graph): Availability of registered products (L) – WHO EML
5 5 5
4 4
3 3
2 2 2 2
1 1 1 1 1
0 0 0 0 0 0
0
1
2
3
4
5
6

FIG. 73 – Summary (graph): Availability of registered products (L) – National EML
78
60
40
35 34 33 32 31 31
27
17
9
7 7
5 4 3
0
10
20
30
40
50
60
70
80
90

FIG. 74A – Summary (graph): Availability of registered products (L) – WHO
78
60
40 40
35 34 33 33 32 31 31
27
22
20 19 19
17
0
10
20
30
40
50
60
70
80
90

FIG. 74B – Summary (graph): Availability of registered products (L) –
13
11
10 10 10 10
9
8 8
7 7 7 7
6
5 5 5 5
0
2
4
6
8
10
12
14

FIG. 74C – Summary (graph): Availability of registered products (L) – WHO
4 4
3 3
2 2 2 2
1 1 1 1 1
0 0 0 0 0 0
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5

FIG. 75 - Antineoplastic agents (L01): Alkylating agents (L01A)
5
0
4
7
78
2
0
10
20
30
40
50
60
70
80
90
cyclophosphamide chlorambucil ifosfamide bendamustine temozolomide dacarbazine
WHO WHO WHO WHO NL WHO
L01AA01 L01AA02 L01AA06 L01AA09 L01AX03 L01AX04

FIG. 76 - Antineoplastic agents (L01): Antimetabolites (L01B)
33
1
0
6
10
5
33
40
0
5
10
15
20
25
30
35
40
45
methotrexate mercaptopurine tioguanine fludarabine cytarabine fluorouracil gemcitabine capecitabine
WHO, NL WHO WHO WHO WHO WHO WHO WHO, NL
L01BA01 L01BB02 L01BB03 L01BB05 L01BC01 L01BC02 L01BC05 L01BC06

FIG. 77 - Antineoplastic agents (L01): Plant alkaloids and other natural
products (L01C)
2 2
10
5
13
40
0
5
10
15
20
25
30
35
40
45
vinblastine vincristine vinorelbine etoposide paclitaxel docetaxel
WHO WHO WHO WHO WHO WHO
L01CA01 L01CA02 L01CA04 L01CB01 L01CD01 L01CD02

FIG. 78 - Antineoplastic agents (L01): Cytotoxic antibiotics & related
substances (L01D)
0
11
1 1
0
2
4
6
8
10
12
dactinomycin doxorubicin daunorubicin bleomycin
WHO WHO WHO WHO
L01DA01 L01DB01 L01DB02 L01DC01

FIG. 79 - Antineoplastic agents (L01): Other antineoplastic agents (L01X)
8 8
22
0
3 2 1
60
7
1
3
0 0
19
3
0
10
20
30
40
50
60
70
cisplatin
carboplatin
oxaliplatin
procarbazine
rituximab
trastuzumab
bevacizumab
imatinib
erlotinib
asparaginase
hydroxycarbamide
miltefosine
tretinoin
irinotecan
erlotinib
WHO WHO WHO WHO WHO WHO WHO WHO, NL NL WHO WHO WHO WHO WHO NL
L01XA01 L01XA02 L01XA03 L01XB01L01XC02L01XC03L01XC07 L01XE01 L01XE03 L01XX02 L01XX05 L01XX09 L01XX14 L01XX19 L01XX34

FIG. 80 – Endocrine therapy (L02)
10
4
5
34
31
32
17
0
5
10
15
20
25
30
35
40
leuprorelin tamoxifen flutamide bicalutamide anastrozole letrozole exemestane
WHO WHO, NL NL WHO, NL WHO, NL NL NL
L02AE02 L02BA01 L02BB01 L02BB03 L02BG03 L02BG04 L02BG06

FIG. 81 – Immunostimulants (L03)
19
20
7
0
5
10
15
20
25
filgrastim peginterferon alfa-2b* peginterferon alfa-2a*
WHO WHO WHO
L03AA02 L03AB10 L03AB11

FIG. 82 - Immunosuppressants (L04)
31
27
10
35
9
7
0
5
10
15
20
25
30
35
40
mycophenolic acid leflunomide ciclosporin tacrolimus azathioprine methotrexate
NL NL WHO NL WHO, NL NL
L04AA06 L04AA13 L04AD01 L04AD02 L04AX01 L04AX03

Unavailable WHO EML
L01AA02 chlorambucil
L01BB03 tioguanine
L01DA01 dactinomycin
L01XB01 procarbazine
L01XX09 miltefosine
L01XX14 tretinoin

MUSCULO-SKELETAL
SYSTEM (M)

FIG. 83 – Summary (graph): Availability of registered products (M) – WHO EML
73
6
2 1 0 0
0
10
20
30
40
50
60
70
80
ibuprofen allopurinol vecuronium atracurium penicillamine suxamethonium

FIG. 84 – Summary (graph): Availability of registered products (M) – National EML
96
73
40
27 26
18 18 18
13 12
9 8 6 5 4 4 4 4
0
20
40
60
80
100
120

FIG. 85 – Summary (graph): Availability of registered products (M) – WHO
96
73
40
27 26
18 18 18
13 12
9 8 6 6 5 4 4 4 4 2 1 0 0
0
20
40
60
80
100
120

FIG. 86 – Musculoskeletal system (M): Anti-inflammatory and anti-rheumatic
products (M01)
40
9
27
73
12
8
26
18
5 4
0
0
10
20
30
40
50
60
70
80
diclofenac
piroxicam
meloxicam
ibuprofen
naproxen
celecoxib
etoricoxib
glucosamine
nimesulide
chondroitinsulfate
penicillamine
NL NL NL WHO, NL NL NL NL NL NL NL WHO
M01AB05 M01AC01 M01AC06 M01AE01 M01AE02 M01AH01 M01AH05 M01AX05 M01AX17 M01AX25 M01CC01

FIG 87 – Musculoskeletal system (M): Topical products for joint and muscular
pain (M02), muscle relaxants (M03)
4
13
0
2
1
4
18
0
2
4
6
8
10
12
14
16
18
20
ibuprofen diclofenac suxamethonium vecuronium atracurium baclofen tolperisone
NL NL WHO WHO WHO NL NL
M02AA13 M02AA15 M03AB01 M03AC03 M03AC04 M03BX01 M03BX04

FIG. 88 – Musculoskeletal system (M): Anti-gout preparations (M04), drugs for
the treatment of bone diseases (M05)
6 6
4
96
18
0
20
40
60
80
100
120
allopurinol allopurinol clodronic acid ibandronic acid risedronic acid
NL WHO NL NL NL
M04AA01 M04AA01 M05BA02 M05BA06 M05BA07

Unavailable WHO EML
M01CC01 penicillamine
M03AB01 suxamethonium

NERVOUS SYSTEM (N)

FIG. 89A – Summary (graph): Availability of registered products (N) – WHO EML
76
43
37
16 15 15 14
12 12 11 10 9 8 8 7 7 6
0
10
20
30
40
50
60
70
80

FIG. 89B – Summary (graph): Availability of registered products (N) – WHO EML
5 5 5 5
4 4
3
2 2 2 2 2 2
1 1 1 1 1
0 0
0
1
2
3
4
5
6

FIG. 90A – Summary (graph): Availability of registered products (N) – National EML
249
169
129
118
94 89 82 78 77 71 65 63 57 57 52 50 43 42 37 36
0
50
100
150
200
250
300

FIG. 90B – Summary (graph): Availability of registered products (N) – National EML
33
31 31
29
28
23 23
22
20
18
17
16 16
15
14 14
12
11
10
0
5
10
15
20
25
30
35

FIG. 90C – Summary (graph): Availability of registered products (N) – National EML
9 9
8 8
7
6 6 6 6 6
5 5
4 4 4 4
3 3 3
2 2 2 2
0
1
2
3
4
5
6
7
8
9
10

FIG. 91A – Summary (graph): Availability of registered products (N) – WHO
249
169
129
118
94 89 82 78 77 76 71 65 63 57 57 52 50 43 42 37 36
0
50
100
150
200
250
300

FIG. 91B – Summary (graph): Availability of registered products (N) – WHO
33
31 31
29
28
23 23
22
20
18
17
16 16
15 15 15
14 14 14
12 12
11
0
5
10
15
20
25
30
35

FIG. 91C – Summary (graph): Availability of registered products (N) – WHO
10
9 9
8 8 8
7 7 7
6 6 6 6 6
5 5 5 5 5
4 4 4
0
2
4
6
8
10
12

FIG. 91D – Summary (graph): Availability of registered products (N) – WHO
4 4 4
3 3 3 3
2 2 2 2 2 2 2 2 2
1 1 1 1 1
0 0
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5

FIG. 92 – Anesthetics (N01): General anesthetics (N01A)
0
2 2
3
1
15
9
0
2
4
6
8
10
12
14
16
halotane isoflurane desflurane sevoflurane ketamine propofol nitrous oxide
WHO WHO, NL NL NL WHO WHO WHO, NL
N01AB01 N01AB06 N01AB07 N01AB08 N01AX03 N01AX10 N01AX13

FIG. 93 – Anesthetics (N01): Local anesthetics (N01B)
7 7
2
0
1
2
3
4
5
6
7
8
bupivacaine lidocaine lidocaine,
combinations
WHO WHO WHO
N01BB01 N01BB02 N01BB52

FIG. 94 – Analgesics (N02): Opioids (N02A)
12
5
16
77
29
0
10
20
30
40
50
60
70
80
90
morphine hydromorphone oxycodone fentanyl tramadol
WHO WHO WHO, NL NL NL
N02AA01 N02AA03 N02AA05 N02AB03 N02AX02

FIG. 95 – Analgesics (N02): Other analgesics and antipyretics (N02B) and
antimigraine products (N02C)
14
18
3
43
20
7
0
5
10
15
20
25
30
35
40
45
50
acetylsalicylic acid metamizole sodium metamizole sodium,
combinations excl.
psycholeptics
paracetamol sumatriptan zolmitriptan
WHO NL NL WHO, NL NL NL
N02BA01 N02BB02 N02BB52 N02BE01 N02CC01 N02CC03

FIG. 96 – Antiepileptics (N03)
2 2 0
9 11 12
65
52
23
118
129
0
20
40
60
80
100
120
140
phenobarbital
phenytoin
ethosuximide
clonazepam
carbamazepine
valproicacid
lamotrigine
topiramate
gabapentin
levetiracetam
pregabalin
WHO WHO WHO NL WHO, NL WHO, NL NL NL NL NL NL
N03AA02 N03AB02 N03AD01 N03AE01 N03AF01 N03AG01 N03AX09 N03AX11 N03AX12 N03AX14 N03AX16

FIG. 97 – Anti-Parkinson drugs (N04)
2
10
57
82
94
14
6
0
10
20
30
40
50
60
70
80
90
100
biperiden levodopa and
decarboxylase
inhibitor
levodopa,
decarboxylase
inhibitor and COMT
inhibitor
ropinirole pramipexole rasagiline entacapone
WHO WHO, NL NL NL NL NL NL
N04AA02 N04BA02 N04BA03 N04BC04 N04BC05 N04BD02 N04BX02

FIG. 98 – Psycholeptics (N05): Antipsychotics (N05A)
1 1 4
31
5
249
169
3
14
1
76
89
0
50
100
150
200
250
300
chlorpromazine
fluphenazine
haloperidol
ziprasidone
clozapine
olanzapine
quetiapine
tiapride
amisulpride
lithium
risperidon
aripiprazole
WHO WHO WHO NL WHO, NL NL NL NL NL WHO WHO NL
N05AA01 N05AB02 N05AD01 N05AE04 N05AH02 N05AH03 N05AH04 N05AL03 N05AL05 N05AN01 N05AX08 N05AX12

FIG. 99 – Psycholeptics (N05): Anxiolytics (N05B)
5
2
6
23
4
0
5
10
15
20
25
diazepam chlordiazepoxide lorazepam alprazolam buspirone
WHO NL WHO, NL NL NL
N05BA01 N05BA02 N05BA06 N05BA12 N05BE01

FIG. 100 – Psycholeptics (N05): Hyponotics and sedatives (N05C)
15
2
8
17
6
0
2
4
6
8
10
12
14
16
18
midazolam brotizolam zopiclone zolpidem zaleplon
WHO NL NL NL NL
N05CD08 N05CD09 N05CF01 N05CF02 N05CF03

FIG. 101 – Psychoanaleptics (N06): Antidepressants (N06A)
5 4
8
31
16
28
78
4 4
42
6
63
36
0
10
20
30
40
50
60
70
80
90
clomipramin
amitriptylin
fluoxetin
citalopram
paroxetine
sertraline
escitalopram
moclobemide
mianserin
mirtazapine
tianeptine
venlafaxine
duloxetine
WHO WHO WHO, NL NL NL NL NL NL NL NL NL NL NL
N06AA04 N06AA09 N06AB03 N06AB04 N06AB05 N06AB06 N06AB10 N06AG02 N06AX03 N06AX11 N06AX14 N06AX16 N06AX21

FIG. 102 – Psychoanaleptics (N06): Psychostimulants, agents used for ADHD
and nootropics (N06B) and anti-dementia drugs (N06D)
15
3
22
5
50
71
57
0
10
20
30
40
50
60
70
80
atomoxetine caffeine citrate piracetam vinpocetine donepezil rivastigmine memantine
NL WHO NL NL NL NL NL
N06BA09 N06BC01 N06BX03 N06BX18 N06DA02 N06DA03 N06DX01

FIG. 103 – Other nervous system drugs (N07): Parasympathomimetics
(N07A), drugs used in addictive disorders (N07B), anti-vertigo preparations
(N07C) and other (N07X)
2
1
37
6
8
33
4
0
5
10
15
20
25
30
35
40
neostigmine pyridostigmine nicotine buprenorphine methadone betahistine riluzole
WHO WHO WHO, NL NL WHO NL NL
N07AA01 N07AA02 N07BA01 N07BC01 N07BC02 N07CA01 N07XX02

Unavailable WHO EML
N01AB01 halotane
N03AD01 ethosuximide

ANTIPARASITIC PRODUCTS,
INSECTICIDES AND
REPELLENTS (P)

FIG. 104 – Summary (graph): Availability of registered products (P) – WHO EM
List and National EM List combined
3
2
1 1 1 1 1
0
0.5
1
1.5
2
2.5
3
3.5
metronidazole levamisole chloroquine mefloquine mebendazole albendazole permethrin

FIG. 105 – Antiparasitics, insecticides and repellents (P): Antiprotozoals
(P01), anthelmintics (P02) and ectoparasiticides (P03)
3
2
1 1 1 1 1
0
0.5
1
1.5
2
2.5
3
3.5
metronidazole levamisole chloroquine mefloquine mebendazole albendazole permethrin
P01AB01 P02CE01 P01BA01 P01BC02 P02CA01 P02CA03 P03AC04

FIG. 106 – Antiparasitics, insecticides and repellents (P) – WHO EML unavailable
P01AC01 diloxanide
P01BA02 hydroxychloroquine
P01BA03 primaquine
P01BA06 amodiaquine
P01BB01 proguanil
P01BC01 quinine
P01BD01 pyrimethamine
P01BD51 pyrimethamine, comb.
P01BE02 artemether
P01BE03 artesunate
P01BF01 artemether and lumefantrine
P01BF02 artesunate and mefloquine
P01BF03 artesunate and amodiaquine
P01CA02 benznidazole
P01CB01 meglumine antimoniate
P01CB02 sodium stibogluconate
P01CC01 nifurtimox
P01CD01 melarsoprol
P01CX01 pentamidine isethionate
P01CX02 suramin sodium
P01CX03 eflornithine
P02BA01 praziquantel
P02BA02 oxamniquine
P02BX04 triclabendazole
P02CB02 diethylcarbamazine
P02CC01 pyrantel
P02CF01 ivermectin
P02DA01 niclosamide
P03AX01 benzyl benzoate

RESPIRATORY SYSTEM (R)

FIG. 107 – Summary (graph): Availability of registered products (R) – WHO
97
56
28 26
22
18 16 16 16 15 12 11 9 8 7
0
20
40
60
80
100
120

FIG. 108 – Summary (graph): Availability of registered products (R) – WHO
7
6
5 5 5
4 4
3 3 3
2
1
0 0 0
0
1
2
3
4
5
6
7
8

FIG. 109 – Respiratory system (R): Nasal preparations (R01)
16
9
5
3
7
4 4
0
2
4
6
8
10
12
14
16
18
xylometazoline xylometazoline,
combinations
budesonide fluticasone mometasone fluticasone,
combinations
pseudoephedrine,
combinations
WHO, NL NL WHO NL NL NL NL
R01AA07 R01AB06 R01AD05 R01AD08 R01AD09 R01AD58 R01BA52

FIG. 110 – Respiratory system (R): Throat preparations (R02) and drugs for
obstructive airway diseases (R03)
6 7 8
22
28
0
15
5 5
1
97
0
20
40
60
80
100
120
flurbiprofen
salbutamol
formoterol
salmeterolandfluticasone
formoterolandbudesonide
beclometasone
budesonide
ipratropiumbromide
tiotropiumbromide
salbutamol
montelukast
NL WHO, NL NL NL NL WHO NL WHO, NL NL WHO NL
R02AX01 R03AC02 R03AC13 R03AK06 R03AK07 R03BA01 R03BA02 R03BB01 R03BB04 R03CC02 R03DC03

FIG. 111 – Respiratory system (R): Cough and cold preparations (R05)
11
26
0
2
0
5
10
15
20
25
30
carbocisteine ambroxol codeine prenoxdiazine
NL NL WHO NL
R05CB03 R05CB06 R05DA04 R05DB18

FIG. 112 – Respiratory system (R): antihistamines for systemic use (R06) and
other respiratory system products (R07)
0
18
16
12
16
56
3 3
0
10
20
30
40
50
60
cyclizine cetirizine levocetirizine loratadine fexofenadine desloratadine Lung surfactants nitric oxide
WHO NL NL WHO, NL NL NL WHO NL
R06AE03 R06AE07 R06AE09 R06AX13 R06AX26 R06AX27 R07AA R07AX01

Unavailable WHO EML
R03BA01 beclometasone
R05DA04 codeine
R06AE03 cyclizine

SENSORY ORGANS (S)

FIG. 113 – Summary (graph): Availability of registered products (S) – WHO
31
13
8 7
5 4 4 4 4 4 3 2 2 2 2 2 2 2 1 1 1 1 1 0 0 0 0 0 0
0
5
10
15
20
25
30
35

FIG. 114 – Ophthalmologicals (S01): Antiinfectives (S01A)
0 0
4
1
2 2
1
3
2
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
tetracycline gentamicin tobramycin aciclovir ofloxacin levofloxacin moxifloxacin Other
antiinfectives
Other
antiinfectives
WHO WHO NL WHO NL NL NL NL NL
S01AA09 S01AA11 S01AA12 S01AD03 S01AE01 S01AE05 S01AE07 S01AX11 S01AX22

FIG. 115 – Ophthalmologicals (S01): Antiinflammatory agents (S01B),
Antiinflammatory angents and antiinfectives in combination (S01C),
antiglaucoma preparations and miotics (S01E)
0
2
4
0
2 1
8
1
4
31
13
4 5
0
5
10
15
20
25
30
35
prednisolone
fluorometholone
dexamethasoneandantiinfectives
epinephrine
pilocarpine
acetazolamide
dorzolamide
brinzolamide
timolol
timolol,combinations
latanoprost
bimatoprost
travoprost
WHO NL NL WHO WHO WHO NL NL WHO, NL NL WHO, NL NL NL
S01BA04 S01BA07 S01CA01 S01EA01 S01EB01 S01EC01 S01EC03 S01EC04 S01ED01 S01ED51 S01EE01 S01EE03 S01EE04

FIG. 116 – Ophthalmologicals (S01): Mydriatics and cycloplegics (S01F),
decongestants and antiallergics (S01G), local anesthetics (S01H), and
diagnostic agents (S01J)
0
1
7
2
4
0
2
0
1
2
3
4
5
6
7
8
atropine tropicamide cromoglicic acid azelastine olopatadine tetracaine fluorescein
WHO WHO NL NL NL WHO WHO
S01FA01 S01FA06 S01GX01 S01GX07 S01GX09 S01HA03 S01JA01

Unavailable WHO EML
S01AA09 tetracycline
S01AA11 gentamicin
S01BA04 prednisolone
S01EA01 epinephrine
S01FA01 atropine
S01HA03 tetracaine

VARIOUS (V)

FIG. 117 – Summary (graph): Availability of registered products (V) – WHO EM
List and National EM List combined
16
13 13
8
5
4
3 3
2
1 1 1 1
0 0 0 0 0 0 0 0 0
0
2
4
6
8
10
12
14
16
18

FIG. 118 – Various (V): All other therapeutic products (V03)
0 0 0 0
1
3
2
1
0 0
1
13
1
5
13
0
2
4
6
8
10
12
14
edetates
thiosulfate
sodiumnitrite
dimercaprol
protamine
naloxone
methylthioniniumchloride
(methyleneblue)
acetylcysteine
potassiumferric
hexacyanoferrate(II)·2H2O
(Prussianblue)
fomepizole
deferoxamine
sevelamer
mesna
calciumfolinate
oxygen
WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO WHO NL WHO WHO WHO, NL
V03AB03V03AB06V03AB08V03AB09V03AB14V03AB15V03AB17V03AB23V03AB31V03AB34V03AC01V03AE02V03AF01V03AF03V03AN01

FIG. 119 – Various (V): Diagnostic agents (V04), all other non-therapeutic
products (V07) and contrast media (V08)
0
16
0
4
3
0
8
0
2
4
6
8
10
12
14
16
18
tuberculin, purified
protein derivative
(PPD) - BCG
Water for Injection Technical
disinfectants
diatrizoic acid iohexol iotroxic acid barium sulfate with
suspending
agents
V04CF01 V07AB V07AV V08AA01 V08AB02 V08AC02 V08BA01

Unavailable WHO EML
V03AB03 edetates
V03AB06 thiosulfate
V03AB08 sodium nitrite
V03AB09 dimercaprol
V03AB31 potassium ferric hexacyanoferrate (II) 2H2O (Prussian blue)
V03AB34 fomepizole
V04CF01 tuberculin, purified protein derivative (PPD) - BCG
V07AV Technical disinfectants
V08AC02 iotroxic acid

ARETE-ZOE, as a consultancy, provides solutions to complex problems in the
high stakes and high consequence environment of Global Pharmaceuticals,
including clinical research, healthcare informatics, and public
health. We blend established, Pharma sector methodologies, innovation, and
adaptations/transfers from other sectors to identify and resolve consequential
practices that pose risk and often result in avoidable patient casualty. However,
we are specifically, not a patient advocacy group but believe in optimizing
organizational effectiveness and that smart business is agile, competitive and
profitable, while intrinsically safe, secure, and resilient. We work within a global
context because transnational interests influence national circumstances and
choices at point of prescription.
ARETE-ZOE, provides full spectrum organizational and operational risk
management consultancy. Our published materials provide a glimpse of some
aspects of our services to demonstrate both knowledge and ongoing participation
within the Pharmaceutical Industry. Our analysis and consultancy includes all
channels of misuse, diversion, counterfeiting and illicit exploitation of
pharmaceuticals, medical devices, and precursor chemicals. Our advisement is to
manufactures, jurisdictional entities, insurers, legislators, litigators, patients, and
health care providers.
This scope also frequently segues into the nexus of crime and terrorism as
significant influencers that undermine sector integrity differentiated from other
criminal activity. Obviously, vulnerability assessment, information collection
management and intelligence production supporting decision-making for risk
reduction and interventions are routinely within the scope of our services as well
as design and implementation of operational control measures.

Essential medicines in Hungary

Recommended

Recommended

More Related Content

Similar to Essential medicines in Hungary

Similar to Essential medicines in Hungary (19)

More from Arete-Zoe, LLC

More from Arete-Zoe, LLC (20)

Recently uploaded

Recently uploaded (19)

Essential medicines in Hungary